Mabpharm Limited (MABPHARM-B) reported no changes in its share capital structure for the month ended 31 July 2026, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Limited on 4 August 2026.

Authorised and Issued Share Capital • Authorised share capital remained unchanged at 50.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 5.00 million. • Issued share capital stood at 4.12 billion ordinary shares, with zero treasury shares, the same level as at end-June 2026. No new shares were issued, repurchased, or cancelled during the period.

Public Float • MABPHARM-B confirmed that it met the Main Board’s minimum public float threshold of 25% as at 31 July 2026.

Share Option Scheme • Outstanding options under the company’s 10 August 2018 Share Option Scheme totalled 72.67 million, unchanged month-on-month. No options were exercised, granted, or cancelled, and no shares were issued or transferred from treasury during July.

Other Equity Instruments • The company reported no outstanding warrants, convertible securities, or other equity-linked instruments, and no additional arrangements to issue shares.

Governance • The filing was authorised by company secretary Tsang Ho Yin, reinforcing compliance with Hong Kong listing disclosure requirements.

Overall, MABPHARM-B entered August 2026 with an unchanged capital base, steady option overhang, and a public float comfortably above the regulatory minimum.